×

Biotech and Pharmaceuticals Medicine

  • Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now. In a study Thursday in the journal Science, Johns Hopkins University scientists looked to see how well their experimental test detected cancer in people already known to have the disease.

  • Aurora, Canada's second largest pot producer, will export medical cannabis into Germany through Pedanios, which will supply the Italian market through the Italian Ministry of Defence. Cannabis-based medicines are legal in several European Union countries including Italy as a treatment for chronic pain, post-traumatic stress disorder, side effects from...

  • Retail prescriptions set to reach $4 billion this year.

    Several major hospital systems plan to form a drug company that will provide generic drugs in short supply to the hospitals, the New York Times reports.

  • INDIAN HEALTH MINISTER HAD SOUGHT $10 BLN BUDGET FOR STEPPING UP DISEASE CONTROL- LETTER.

  • PHILADELPHIA— Health insurer Aetna has agreed to pay $17 million to settle claims that it breached the privacy of thousands of customers who take HIV medications. Attorneys for the plaintiffs announced the settlement Wednesday in Philadelphia. Court documents say the Hartford, Connecticut- based company sent a mailing in envelopes with large, clear display...

  • An Animas insulin pump.

    Chinese bidders are circling a diabetes care business owned by the world’s largest healthcare company, Johnson & Johnson.

  • PHILADELPHIA— Philadelphia has filed a lawsuit against drug companies that make prescription opioids, saying they've created "an unprecedented public health crisis." It seeks to halt what the city calls "deceptive marketing practices" and force the drug makers to pay for treatment costs and reimburse the city for the money it has spent responding to the...

  • **Cancer drug developer's shares up as much as 53.16 pct to $2.67- biggest intraday pct gain in more than 3 months. **Says an independent data monitoring committee recommended co to continue its late-stage study of its lead drug, rigosertib, in patients with higher-risk myelodysplastic syndromes. **IMDC recommends co to increase enrollment by adding 135 patients...

  • New Brunswick, N.J.- based J&J said in January last year it was evaluating options for its diabetes care companies, specifically LifeScan Inc, Animas Corp, and Calibra Medical Inc. One option was a sale of the business, it said. Almost one in three of the world's diabetes sufferers lives in China, according to World Health Organisation estimates.

  • Jan 16- Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its drug to treat pulmonary arterial hypertension, a type of high blood pressure, after it failed in a mid-stage study. The drug developer's shares slumped about 39 percent to $9.7 in premarket trading. The drug, ubenimex, failed the main goal of improving pulmonary vascular...

  • Jan 16- Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

  • The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy. Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. Susan M. Domchek at the University of Pennsylvania's Abramson Cancer Center said in a statement.

  • BUCHAREST, Romania— A court has ruled that a top Romanian doctor charged with using state-owned equipment and other resources for his private clinic should be placed under house arrest. The Bucharest Court of Appeal ruled Friday that Mihai Lucan, a well-connected urologist from the northwestern city of Cluj, would be detained at home over charges he embezzled...

  • Dr. Anne Furey Schultz examines a patient complaining of flu-like symptoms at Northwestern Memorial Hospital in Chicago.

    CNBC's Meg Tirrell breaks down factors from the worst flu season since 2010 and the effectiveness of the current flu shot.

  • Jan 11- Pharmaceutical company Endo International Plc said on Thursday it had received a grand jury subpoena from federal prosecutors in Miami seeking documents related to drugs it produces that contain the opioid painkiller oxymorphone. They have generally argued the U.S. Food and Drug Administration approved their products as safe and effective and...

  • COLUMBUS, Ohio— Ohio residents with work-related back injuries in most cases must try remedies like rest, physical therapy and chiropractic care before turning to spinal fusion surgery and prescription painkillers under a groundbreaking new guideline that is partly meant to reduce the overprescribing of opioids but isn't sitting well with everyone.

  • Jan 9- U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday. Bluebird expects to file for approval this year for its treatment for transfusion-dependent beta thalassemia, which is intended to...

  • Valeant CEO: We took an appropriate response to pricing with recent increase

    At the J.P. Morgan Health Care Conference, Valeant CEO Joe Papa speaks with CNBC's Meg Tirrell about the turnaround in the company and their drug pricing strategy.

  • Jan 9- U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, Chief Executive Nick Leschly announced on Tuesday. Bluebird expects to file for approval this year for its treatment for transfusion-dependent beta thalassemia, which is intended to...

  • Jan 9- U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, Chief Executive Nick Leschly announced on Tuesday. Bluebird expects to file for approval this year for its treatment for transfusion-dependent beta thalassemia, which is intended to...